Oppenheimer & Co’s Protara Therapeutics TARA Stock Holding History

Oppenheimer & Co’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$946K	Sell	181,565 -42,202	-19%	-$250K	0.01%	888
2025 Q4	$1.19M	Buy	223,767 +16,794	+8%	+$93.4K	0.02%	730
2025 Q3	$900K	Sell	206,973 -39,091	-16%	-$127K	0.01%	948
2025 Q2	$746K	Buy	246,064 +59,500	+32%	+$205K	0.01%	984
2025 Q1	$795K	Sell	186,564 -14,862	-7%	-$66.4K	0.01%	899
2024 Q4	$1.06M	Buy	201,426 +22,301	+12%	+$72K	0.02%	755
2024 Q3	$328K	Buy	179,125 +51,944	+41%	+$107K	0.01%	1190
2024 Q2	$265K	Buy	127,181 +117,181	+1,172%	+$343K	﹤0.01%	1240
2024 Q1	$40.1K	Buy	+10,000	New	+$32.3K	﹤0.01%	1418

Other funds holding TARA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Oppenheimer & Co's TARA Position: Q1 2026 in Review

Oppenheimer & Co reduced its Protara Therapeutics (TARA) stake by 19% in Q1 2026, selling an estimated $250K and leaving 181,565 shares worth $946K. The position accounts for 0.01% of the portfolio, ranked #888.

Oppenheimer & Co first reported a position in TARA in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.19M in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

Oppenheimer & Co held 181,565 shares of Protara Therapeutics worth $946K as of Q1 2026.
Oppenheimer & Co sold 42,202 Protara Therapeutics shares in Q1 2026, an estimated $250K.
Protara Therapeutics made up 0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #888 holding.
Oppenheimer & Co first reported a position in Protara Therapeutics in Q1 2024 and has held it in 9 quarters since.
Oppenheimer & Co's Protara Therapeutics position peaked at $1.19M in Q4 2025.
114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.